BioSpace News Archive

Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company, today announced that Prometic Plasma Resources, a subsidiary of Liminal BioSciences Inc., has joined the CoVIg-19 Plasma Alliance to contribute to the accelerat

Today Berkeley Lights, Inc., a leader in Digital Cell Biology, announced the appointment of Gregory T. Lucier to the Berkeley Lights Board of Directors

A New Lab to Study the Impact of Lived Experiences on Developing Alzheimer’s Disease

Women’s Care Enterprises announces that Alistair Madle has rejoined the company as its chief executive officer.

As part of continued action to protect the American public, the U.S. Food and Drug Administration is warning consumers and health care professionals about hand sanitizer products containing methanol, or wood alcohol — a substance often used to create fuel and antifreeze that is not an acceptable active ingredient for hand sanitizer products and can be toxic when absorbed through the skin as well as life-threatening when ingested.

RTI Surgical Holdings, Inc. (Nasdaq: RTIX), a global surgical implant company, today announced that, due to the public health impact of the coronavirus outbreak (COVID-19), its Annual Meeting of Stockholders, to be held on Wednesday, July 15, 2020 at 9:00 a.m. Central Daylight Time (the “Annual Meeting”)

Protara Therapeutics, Inc., a development-stage clinical biopharmaceutical company developing treatments for rare and specialty diseases with significant unmet needs, announced the grants of inducement non-qualified stock options to purchase an aggregate of 3,700 shares of common stock to one new employee.

ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (OTC: IMUC), today announced that, based on the vote count following the Special Meeting of Stockholders held June 26 , 2020, stockholders voted in favor of the proposal to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stoc

Akebia Therapeutics®, Inc. granted six newly-hired employees options to purchase an aggregate of 320,000 shares of Akebia’s common stock on June 30, 2020, including an option to purchase 280,000 shares granted to David Spellman, Akebia’s newly-hired Senior Vice President, Chief Financial Officer.

Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2020 second quarter financial results after the close of the market on Thursday, July 30th